Telix Pharmaceuticals has swung to a half-year profit of $38.3 million, compared with a loss of $2.3 million in the prior year period, marking a significant milestone for the nuclear medicine company as it scales commercialisation of its imaging products in the United States. The turnaround reflects strong revenue momentum, with sales climbing 22 percent to $477.4 million in the six months to June 30, 2026, driven primarily by increasing uptake of its two approved products, Illuccix and Gozellix, in the U.S. market where the company has been building commercial infrastructure and field teams.
The company’s gross profit expanded substantially from $208.6 million to $260.3 million, demonstrating improving operational leverage as it pushes through the peak commercialisation spending phase. Underlying operating profit reached $46.4 million, more than quadrupling the prior year’s $10.4 million result, though this improvement was materially assisted by a $40 million credit from a collaboration with Regeneron Pharmaceuticals announced during the period. Excluding this one-off income, the company would have reported operating profit closer to $6.4 million, underscoring the strategic importance of the partnership deal and its contribution to near-term financial performance.
Research and development investment rose significantly to $123.8 million from $81.6 million, reflecting Telix’s pipeline expansion as it pursues regulatory approvals and clinical development for additional assets. Operating expenses climbed to $259.6 million overall, representing the ongoing cost of building scale in commercial infrastructure, manufacturing capability, and regulatory functions across multiple markets. Finance costs remained relatively stable at $19.4 million against the prior period’s $18.8 million, suggesting the company’s debt servicing position has remained manageable despite the continued investment in growth and development.
Earnings per share improved sharply to 11.3 cents from negative 0.68 cents, while the company continued its policy of retaining cash, with no dividend proposed for shareholders. Management commentary emphasises the underlying strength in U.S. commercial execution and positions the Regeneron collaboration as validation of Telix’s technology platform, with potential for expanding the partnership to additional assets within both companies’ combined portfolios.
Investors will be watching for quarterly revenue trends from the two U.S. products to confirm sustained momentum, clarity on cash runway given the accelerating investment profile across development and commercial operations, and progress on the expanding partnership with Regeneron. The company faces the typical challenge of a scaling biotech firm, where near-term statutory profitability masks significant ongoing cash burn across research, development, and commercial operations. The announcement is price sensitive and has been flagged as material by the ASX.
View the full ASX announcement (PDF)
About TELIX Pharmaceuticals Limited (ASX: TLX)
TELIX Pharmaceuticals Limited is a commercial-stage biopharmaceutical company that develops and commercializes therapeutic and diagnostic radiopharmaceuticals for oncology and other serious diseases. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions, focusing on targeted radiation therapies for various cancer indications. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally.
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
